Anti-Allergy Medicine EpiPen Recall Expands to US

Anti-Allergy Medicine EpiPen Recall Expands to US

Anti-Allergy Medicine EpiPen Recall Expands to US

The products affected would have been distributed to consumers between December 17, 2015, and July 1, 2016. Mylan's new generic EpiPen is not part of the voluntary recall and has been deemed a suitable replacement for the potentially defective product. The recalled product was manufactured by Meridian Medical Technologies and distributed by Mylan Specialty, according to the FDA's press release dated March 31, 2017.

"There will be no additional replacement-related financial burden to [patients] as a result of this recall", Mylan said.

The initial recall of the emergency allergy product didn't include the USA, but Mylan issued a new recall last night which not only includes EpiPens sold in the United States, but also involves the children's version, known as EpiPen Jr. (0.15 mg) are sold as 2 Pak Auto-Injectors. Mylan brands adult versions with a yellow label and junior devices with a green label.

Читайте также: US stock indexes mostly down in afternoon trading; oil rises

EpiPens are used to give an emergency injection of epinephrine to treat life-threatening allergic reactions. The recall does not include Mylan's cheaper generic version that the company released late past year.

Mylan, which is the focus of multiple federal investigations, has come under fire for staggering price increases on the emergency shot in the United States. The new recall not only covers EpiPens sold in the US, but also involves the children's version, known as EpiPen Jr.

The recalled items will be replaced at no cost. Food and Drug Administration.

При любом использовании материалов сайта и дочерних проектов, гиперссылка на обязательна.
«» 2007 - 2017 Copyright.
Автоматизированное извлечение информации сайта запрещено.

Код для вставки в блог

Related news